HYUNDAI PHARMACEUTICAL CO., LTD Q3 (Jun-Aug) operating profit KRW 2.4 billion, down from KRW 3.5 billion a year earlier
HAI summary · Not investment advice
HYUNDAI PHARMACEUTICAL CO., LTD posted Q3 (Jun-Aug) separate revenue of KRW 56.3 billion and operating profit of KRW 2.4 billion, versus KRW 3.5 billion a year earlier.
Operating profit · 3 months
KRW 2.4 billion
KRW 3.5 billion in the same period a year earlier
Key facts
- Revenue (3 months)
- KRW 56.3 billion
- Net income (3 months)
- KRW 1.7 billion
- Period
- Q3 (cumulative 2025.12.01 ~ 2026.08.31)Three months 2026.06.01 ~ 2026.08.31
- Basis
- Separate
- Revenue (prior-year 3 months)
- KRW 51.6 billion
- Revenue (year to date)
- KRW 158.3 billion
- Operating profit (prior-year 3 months)
- KRW 3.5 billion
- Operating profit (year to date)
- KRW 5.9 billion
- Net income (prior-year 3 months)
- KRW 2.5 billion
- Net income (year to date)
- KRW 3.3 billion
Commentary
AI commentary · Not investment advice
What happened
HYUNDAI PHARMACEUTICAL CO., LTD filed its quarterly report for Q3 (June to August 2026). Its fiscal year starts in December. For the three months, revenue was KRW 56.3 billion and operating profit was KRW 2.4 billion. In the same three months a year earlier, revenue was KRW 51.6 billion and operating profit was KRW 3.5 billion. Net profit was KRW 1.7 billion, lower than KRW 2.5 billion a year earlier.
In the company's terms
For the first nine months of the fiscal year, revenue was KRW 158.3 billion. Cumulative operating profit was KRW 5.9 billion and cumulative net profit was KRW 3.3 billion. All figures are on a separate basis, for the company alone without subsidiaries.
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist